Generic Name |
Tinostamustine | |
---|---|---|
IND |
EDO-S101 | |
Brand Name (US) |
||
Manufacturer |
||
Drug Type |
Alkylating histone-deacetylase inhibitor | |
Delivery |
||
Approval Status |
Phase 2 | |
Indications |
||
Overall Strategy |
GIST Tumor Based | |
Strategy |
Interfere with production of new DNA | |
Drug Category |
Tinostamustine (EDO-S101) is a new chemical entity, an AK-DAC (a first-in-class alkylating deacetylase inhibiting molecule) that, in preclinical studies, has been shown to simultaneously improve access to the DNA strands within cancer cells, break them and block damage repair. This Phase 1/2 study will enroll patients with various advanced solid tumors.
Links |
|
Trials of this drug |
|
Trial results |